{Reference Type}: Case Reports
{Title}: Management of the Drug-Drug Interactions Between Valproic Acid and Dolutegravir-A Case Study.
{Author}: Cattaneo D;Giacomelli A;Calvagna N;Bonini I;Ridolfo AL;Gervasoni C;
{Journal}: Ther Drug Monit
{Volume}: 46
{Issue}: 4
{Year}: 2024 Aug 1
{Factor}: 3.118
{DOI}: 10.1097/FTD.0000000000001221
{Abstract}: OBJECTIVE: Preliminary evidence shows that concomitant administration of valproic acid can reduce the exposure to dolutegravir with limited clinical impacts. Here, we describe a male living with HIV who experienced a drastic reduction in dolutegravir trough concentrations a few weeks after starting valproic acid treatment as identified by therapeutic drug monitoring. Concomitantly, pharmacists recommended a supplementation of magnesium to improve insomnia.
METHODS: A 62-year-old man with HIV on antiretroviral therapy with dolutegravir and lamivudine recently added valproic acid to clonazepam and sertraline to treat severe sleep disturbances. An 84% reduction in dolutegravir trough concentrations was observed compared with the previous outpatient visit (418 versus 2714 ng/mL), with values close to the minimum effective drug concentration (300 ng/mL). Considering this, we strongly discourage the use of magnesium.
CONCLUSIONS: We are confident that our findings can contribute to a better understanding of the clinical problems that infectious disease physicians encounter in their daily management of people with HIV and how therapeutic drug monitoring may add value in this context. This case also highlights the importance of multidisciplinary services for the optimal management of polypharmacy in people with HIV.